Latest Breaking News On - Accelerated approval new drug application - Page 1 : vimarsana.com

Trial Analyzing MEK Inhibitor Combo for Ovarian Cancer Subset Begins

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

City ofUnited kingdomRachel grishamSusana banerjeeDan patersonDrug administrationMemorial sloan kettering cancer centerInstitute of cancer researchVerastem oncologyRoyal marsdenCancer researchAccelerated approval new drug applicationBreakthrough therapy designationAccelerated approvalOvarian cancerGynecologic cancer

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofSusana banerjeeRyan porterDan patersonRachel grishamElisa buffingtonResearch lead for the gynaecology unitSecura bio incFoundation incEuropean society of gynaecological oncologyCorporate communicationsNational cancer instituteInstitute of cancer researchEuropean network for gynaecological oncological trial

Verastem Oncology (VSTM) Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology (VSTM) Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomDan patersonRachel grishamSusana banerjeeDrug administrationInstitute of cancer researchFoundation incCompany phaseResearch lead for the gynaecology unitEuropean network of gynaecological oncological trialTeam leader in women cancersVerastem oncologyChief executive officerBreakthrough therapy designationAccelerated approval

Verastem starts Phase 3 study for ovarian cancer drug combination (NASDAQ:VSTM)

Verastem starts Phase 3 study for ovarian cancer drug combination (NASDAQ:VSTM)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Accelerated approval new drug application